Zhejiang Medicine Co., Ltd.

600216

CNE0000010J2

Pharmaceuticals

End-of-day quote Shanghai S.E. Other stock markets 06:00:00 2024-05-20 pm EDT			5-day change	1st Jan Change
10.51 ^CNY	-1.22%		-1.78%	-2.05%

Apr. 25	Zhejiang Medicine Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
2023	Zhejiang Medicine Wins Nod to Trial Digestive Acid Drug	MT

Zhejiang Medicine Co., Ltd. Provides Earnings Guidance for the Year 2016

January 12, 2017

Zhejiang Medicine Co., Ltd. provided earnings guidance for the year 2016. The company predicts an increase of between 150% and 200% in the net profit belonging to shareholders of the listed company in 2016 compared with the same period of the year before.

Latest news about Zhejiang Medicine Co., Ltd.

Zhejiang Medicine Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 25	CI
Zhejiang Medicine Wins Nod to Trial Digestive Acid Drug	Nov. 28	MT
Zhejiang Medicine Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-25	CI
Zhejiang Medicine Wins Nod to Trial Anti-Tumor Drug	23-09-19	MT
Zhejiang Medicine’s South Korean Unit Clears Good Manufacturing Practice Inspection	23-08-23	MT
Zhejiang Medicine Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-23	CI
Zhejiang Medicine Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-25	CI
Zhejiang Medicine Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-25	CI
Citic Securities says global financial market fluctuations hurt business	23-03-30	RE
Zhejiang Medicine to Market Antibiotic in the US After Getting FDA Nod; Shares Jump 3%	23-01-30	MT
Zhejiang Medicine Co., Ltd.(SHSE:600216) dropped from Shanghai Stock Exchange Health Care Sector Index	22-12-09	CI
Zhejiang Medicine Unit Gets Clinical Trial Approval For Anti-Biliary Tract Cancer Drug	22-11-01	MT
Zhejiang Medicine Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022	22-10-26	CI
Brokerage CLSA vice-chairman Charles Lin resigns	22-09-26	RE
Zhejiang Medicine Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022	22-08-25	CI
Zhejiang Medicine Co., Ltd.(SHSE:600216) added to Shanghai Stock Exchange Health Care Sector Index	22-06-13	CI
Zhejiang Medicine Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-04-26	CI
TaiGen Biopharmaceuticals Turns to Profit in 2021	22-03-17	MT
Zhejiang Medicine Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2021	21-10-25	CI
Zhejiang Medicine Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2021	21-08-25	CI
Zhejiang Medicine Co., Ltd.(SHSE:600216) dropped from Shanghai Stock Exchange Health Care Sector Index	21-06-11	CI
Zhejiang Medicine Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2021	21-04-22	CI
Zhejiang Health Creation Bio-Technology Co., Ltd. announced that it expects to receive funding from Zhejiang Medicine Co., Ltd.	20-10-26	CI
Zhejiang Medicine Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2020	20-10-22	CI
Zhejiang Medicine Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2020	20-08-25	CI

Chart Zhejiang Medicine Co., Ltd.

Duration

Period

More charts

Company Profile

Zhejiang Medicine Co., Ltd. is a China-based company, principally engaged in the manufacture and distribution of drugs and nourishments. The Company mainly provides nourishments for animals and human, health care products, and chemicals and chemical raw materials, among others. The Company's products include synthetic vitamin E, natural vitamin E soft capsules, Beta carotene, vancomycin hydrochloride for injection and teicoplanin for injection, among others. The Company distributes its products within domestic market and to overseas markets.

Sector

Pharmaceuticals

Calendar

2024-08-22 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Zhejiang Medicine Co., Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

10.51 CNY

Average target price

11 CNY

Spread / Average Target

+4.66%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ZHEJIANG MEDICINE CO., LTD.	-2.05%	1.41B
ELI LILLY AND COMPANY	+37.78%	705B
NOVO NORDISK A/S	+32.82%	583B
JOHNSON & JOHNSON	-3.51%	364B
MERCK & CO., INC.	+19.94%	332B
ABBVIE INC.	+5.14%	291B
ASTRAZENECA PLC	+16.64%	238B
ROCHE HOLDING AG	-4.13%	210B
NOVARTIS AG	+10.63%	209B
AMGEN INC.	+9.32%	169B

Other Pharmaceuticals